Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series.
Future Oncol
; 13(11s): 25-33, 2017 Apr.
Article
en En
| MEDLINE
| ID: mdl-28481183
ABSTRACT
During the last decades, much effort has been made to develop and test treatments for advanced/metastatic breast cancer (MBC) able to prolong survival and improve patients' quality of life. In this regard, eribulin represents one of the most recent and interesting discoveries. This tubulin-targeting chemotherapy demonstrated a survival benefit in MBC women who progressed after at least two prior lines of chemotherapy for the treatment of metastatic disease (prior therapies should have included an anthracycline and a taxane, in either adjuvant or metastatic setting). Here, we described five cases of heavily pretreated MBC patients who experienced long-lasting control of disease with eribulin.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Furanos
/
Cetonas
/
Antineoplásicos
Tipo de estudio:
Clinical_trials
Aspecto:
Patient_preference
Límite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Año:
2017
Tipo del documento:
Article
País de afiliación:
Italia